Pleiotropic effects of statins: new therapeutic targets in drug design (Q38825843)

6 September 2017

1 reference

title

Pleiotropic effects of statins: new therapeutic targets in drug design (English)

1 reference

6 September 2017

1 reference

Onkar Bedi

1

1 reference

6 September 2017

Veena Dhawan

series ordinal

2

1 reference

6 September 2017

P L Sharma

series ordinal

3

1 reference

6 September 2017

Puneet Kumar

series ordinal

4

1 reference

6 September 2017

publication date

5 May 2016

1 reference

Naunyn-Schmiedeberg's Archives of Pharmacology

6 September 2017

published in

1 reference

6 September 2017

volume

389

1 reference

6 September 2017

issue

7

1 reference

6 September 2017

page(s)

695-712

1 reference

Pravastatin provides antioxidant activity and protection of erythrocytes loaded Primaquine

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Production and Purification of Statins from Pleurotus ostreatus (Basidiomycetes) Strains

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

21 January 2018

12 December 2020

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Influence of nicotinic acid on serum cholesterol in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Anti-inflammatory and immunomodulatory effects of statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

The Biological Synthesis of Cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

A novel therapeutic effect of statins on nephrogenic diabetes insipidus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

The Rac and Rho hall of fame: a decade of hypertrophic signaling hits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

A receptor-mediated pathway for cholesterol homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Rho and Rac take center stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: a randomized crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

New insights into the pharmacodynamic and pharmacokinetic properties of statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Repression of IFN-gamma expression by peroxisome proliferator-activated receptor gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by lovastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Low-dose poly(ADP-ribose) polymerase inhibitor-containing combination therapies reverse early peripheral diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Effects of peroxisome proliferator-activated receptor γ in simvastatin antiplatelet activity: influences on cAMP and mitogen-activated protein kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Cholesterol confusion and statin controversy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Statins for the primary prevention of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

A lovastatin-elicited genetic program inhibits M2 macrophage polarization and enhances T cell infiltration into spontaneous mouse mammary tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

A gift from nature: the birth of the statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Safety profile of subjects treated to very low low-density lipoprotein cholesterol levels (<30 mg/dl) with rosuvastatin 20 mg daily (from JUPITER).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Purinergic signaling in atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Rac regulates cardiovascular superoxide through diverse molecular interactions: more than a binary GTP switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

G proteins and small GTPases: distant relatives keep in touch

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Anti-atherogenic effect of statins: role of nitric oxide, peroxynitrite and haem oxygenase-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Anti-atherogenic effects of statins: Impact on angiopoietin-2 release from endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Tissue-specific effects of statins on the expression of heme oxygenase-1 in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Dose-specific effect of simvastatin on hypoxia-induced HIF-1α and BACE expression in Alzheimer's disease cybrid cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Fluvastatin suppresses native and recombinant human P2X4 receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Cerebrovascular disease, the apolipoprotein e4 allele, and cognitive decline in a community-based study of elderly men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Risks associated with statin therapy: a systematic overview of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Protective effect of HMG CoA reductase inhibitors against running wheel activity induced fatigue, anxiety like behavior, oxidative stress and mitochondrial dysfunction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Influence of withdrawal of statin treatment on proinflammatory response and fibrinolytic activity in humans: an effect independent on cholesterol elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Impact of HMG CoA reductase inhibition on small GTPases in the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Rosuvastatin inhibits spontaneous and IL-1β-induced interleukin-6 production from human cultured osteoblastic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: inhibitory effects of atorvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

In vitro modulation of peroxisome proliferator-activated receptor-gamma and its genes by C-reactive protein. Role of atorvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Small leucine-rich proteoglycans in atherosclerotic lesions: novel targets of chronic statin treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

21 January 2018

Cardiorenal dysfunction

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Statins and ATP regulate nuclear pAkt via the P2X7 purinergic receptor in epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Atorvastatin ameliorates sildenafil-induced penile erections in experimental diabetes by inhibiting diabetes-induced RhoA/Rho-kinase signaling hyperactivation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Stimulation of bone formation in vitro and in rodents by statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Attenuation of vascular/neural dysfunction in Zucker rats treated with enalapril or rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Immunomodulatory effects of statins: mechanisms and potential impact on arteriosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Statins do not protect against cancer: quite the opposite

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Beiträge zur Kenntniss des Cholesterins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Role of HMG-CoA Reductase Inhibitors in Neurological Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Rocks: multifunctional kinases in cell behaviour

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Atherosclerosis — An Inflammatory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Statins stimulate in vitro membrane FasL expression and lymphocyte apoptosis through RhoA/ROCK pathway in murine melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

The roles of macrophage autophagy in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

In vitro effects of atorvastatin on lipopolysaccharide-induced gene expression in endometriotic stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Immunomodulator activity of 3-hydroxy-3-methilglutaryl-CoA inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Rebound inflammatory response during the acute phase of myocardial infarction after simvastatin withdrawal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Statin treatment is associated with reduced thermal heterogeneity in human atherosclerotic plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

An investigation into the therapeutic effects of statins with metformin on polycystic ovary syndrome: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Statin therapy for primary prevention of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Statin-induced myopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Atorvastatin protects against deleterious cardiovascular consequences induced by chronic intermittent hypoxia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Inflammatory cytokines in atherosclerosis: current therapeutic approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Simvastatin induces heat shock factor 1 in vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Are prescription drug prices high?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial: a new frontier for statins?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Enhancement of autophagy by simvastatin through inhibition of Rac1-mTOR signaling pathway in coronary arterial myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Role of protein kinase B in insulin-regulated glucose uptake.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Inhibition of Rho and Rac geranylgeranylation by atorvastatin is critical for preservation of endothelial junction integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Current and future treatments for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-016-1252-4

Statins and lipid-lowering strategies in cardiorenal patients.

21 January 2018

1 reference

12 December 2020

Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase

1 reference

12 December 2020

Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial

1 reference

12 December 2020

Mechanism of action of MER-29, an inhibitor of cholesterol biosynthesis

1 reference

12 December 2020

Polycystic Ovary Syndrome (PCOS): Arguably the Most Common Endocrinopathy Is Associated with Significant Morbidity in Women

1 reference

12 December 2020

The HMG-CoA reductase inhibitor pravastatin stimulates insulin secretion through organic anion transporter polypeptides

1 reference

12 December 2020

Possible effects of rosuvastatin on noise-induced oxidative stress in rat brain

1 reference

12 December 2020

The biochemical basis of the biosynthesis of cholesterol and fatty acids

1 reference

12 December 2020

Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry

1 reference

12 December 2020

Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia

1 reference

12 December 2020

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

1 reference

12 December 2020

Ultracentrifugal studies of lipoproteins of human serum.

1 reference

12 December 2020

Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase.

1 reference

12 December 2020

Biosynthesis of cholesterol

1 reference

12 December 2020

Statin efficacy in the treatment of hepatitis C genotype I.

1 reference

12 December 2020

RhoA-mediated, tumor necrosis factor alpha-induced activation of NF-kappaB in rheumatoid synoviocytes: inhibitory effect of simvastatin

1 reference

12 December 2020

Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy

1 reference

12 December 2020

Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries

1 reference

12 December 2020

Pravastatin prevents steroid-induced osteonecrosis in rats by suppressing PPARγ expression and activating Wnt signaling pathway

1 reference

12 December 2020

Statins as a newly recognized type of immunomodulator

1 reference

12 December 2020

Low-Density Lipoprotein Cholesterol and the Risk of Dementia With Stroke

1 reference

12 December 2020

Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages

1 reference

12 December 2020

Rosuvastatin may have neuroprotective effect on spinal cord ischemia reperfusion injury

1 reference

12 December 2020

Structural mechanism for statin inhibition of HMG-CoA reductase

1 reference

12 December 2020

Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro

1 reference

12 December 2020

Fluvastatin modulates renal water reabsorption in vivo through increased AQP2 availability at the apical plasma membrane of collecting duct cells

1 reference

12 December 2020

1 reference

12 December 2020

Protective role of atorvastatin against doxorubicin-induced cardiotoxicity and testicular toxicity in mice

1 reference

12 December 2020

N-WASP, WAVE and Mena play different roles in the organization of actin cytoskeleton in lamellipodia

1 reference

12 December 2020

Serum lipoproteins and the evaluation of atherosclerosis

1 reference

12 December 2020

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

1 reference

12 December 2020

3-Hydroxymethyl coenzyme A reductase inhibition attenuates spontaneous smooth muscle tone via RhoA/ROCK pathway regulated by RhoA prenylation

1 reference

12 December 2020

Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial

1 reference

12 December 2020

Citrinin, an inhibitor of cholesterol synthesis

1 reference

12 December 2020

Sterol metabolism and lymphocyte responsiveness: inhibition of endogenous sterol synthesis prevents mitogen-induced human T cell proliferation

1 reference

12 December 2020

Statins Prevent Dextrose-Induced Endoplasmic Reticulum Stress and Oxidative Stress in Endothelial and HepG2 Cells

1 reference

12 December 2020

Cholesterol-independent effects of atorvastatin prevent cardiovascular morbidity and mortality in a mouse model of atherosclerotic plaque rupture

1 reference

12 December 2020

Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia

1 reference

12 December 2020

Circulating gonadotropins, estrogens, and androgens in polycystic ovarian disease

1 reference

12 December 2020

Specific inhibition of cholesterol biosynthesis by a synthetic compound (MER-29)

1 reference

12 December 2020

10.1007/S00210-016-1252-4

Identifiers

DOI

1 reference

Dimensions Publication ID

6 September 2017

1024596839

0 references

1 reference